Blockbuster drug could be key to Humira’s successor.
FDA’s approval of AbbVie’s upadacitinib (Rinvoq) to treat rheumatoid arthritis (RA) is expected to help the pharma maker stem its losses from future biosimilar competition to adalamumib (Humira).
The 15 mg once-daily oral tablet was approved to treat adults with severely active RA who have had an inadequate response or intolerance to methotrexate (MTX-IR).
Related: FDA Adds Warning To Xeljanz
AbbVie’s Humira, which treats RA, ulcerative colitis, and a number of other inflammatory conditions, will face biosimilar competition in 2023. The blockbuster drug produced 61% of AbbVie's total revenue in 2018, Investor’s Business Dailyreported.
Rinvoq will also help AbbVie compete against other RA blockbusters, including Pfizer’s tofacitinib (Xeljanz) and Lilly/ Incyte’s baracitinib (Olumiant).
"Despite the availability of multiple treatment options with varying mechanisms of action, many patients still do not achieve clinical remission or low disease activity-the primary treatment goals for rheumatoid arthritis," said Roy M. Fleischmann, MD, primary investigator for the SELECT-COMPARE trial and clinical professor at the University of Texas Southwestern Medical Center at Dallas, in an AbbVie statement. ”With this FDA approval, Rinvoq has the potential to help additional people living with RA achieve remission who have not yet reached this goal."
Related: New RA Biosimilar Impact Hinges On Patent Lawsuit
FDA’s approval of Rinvoq is supported by data from one of the largest registrational phase 3 programs in RA, according to AbbVie. Around 4,400 patients were evaluated across all treatment arms in 5 studies.
In SELECT-EARLY, 52% of MTX-naïve patients treated with Rinvoq 15 mg. achieved ACR50 versus 28% treated with MTX at week 12. In SELECT-MONOTHERAPY, 68% of MTX-IR patients treated with Rinvoq 15 mg. achieved ACR20 vs 41% treated with continued MTX at week 14.
Read more: Rheumatoid Arthritis Drug Poses Fatal Side Effects
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More